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NICE has renewed accreditation of the process used by the British
Association of Dermatologists to produce clinical guidelines. The
renewed accreditation is valid until 31 May 2021 and applies to
guidance produced using the processes described in the updated gui-
dance for writing a British Association of Dermatologists clinical
guideline – the adoption of the GRADE methodology 2016. The
original accreditation term began on 12 May 2010. More infor-
mation on accreditation can be viewed at www.nice.org.uk/accred
itation.
Purpose and scope of the guideline
The overall aim of the guideline is to provide up-to-date, evi-
dence-based recommendations on the use of biologic therapies
targeting tumour necrosis factor (TNF) (adalimumab, etanercept,
certolizumab pegol, infliximab), interleukin (IL)-12/23p40
(ustekinumab), IL-17A (ixekizumab, secukinumab), IL-17RA
(brodalumab) and IL-23p19 (guselkumab, risankizumab, tildrak-
izumab) in adults, children and young people for the treatment
of psoriasis; consideration is given to the specific needs of people
with psoriasis and psoriatic arthritis. This rapid update is part of
an annual evidence review to factor in the latest evidence for bio-
logical drugs evaluated in the 2017 publication of the guideline,1
and newer biological drugs that have been licensed for psoriasis
in the UK or are expected to be licensed in the near future.
This set of guidelines has been developed using the recom-
mended methodology of the British Association of Dermatolo-
gists (BAD)2 with reference to the Appraisal of Guidelines
Research and Evaluation (AGREE II) instrument (www.agree-
trust.org),3 and the Grading of Recommendations Assessment,
Development and Evaluation (GRADE).4 Additional online Sup-
porting Material includes our Implementation Toolkit (File S1),
Appendices (File S2), and Audit standards and methodology
(File S3). Further information on the guideline development
process can be found in Appendix I (File S2; see Supporting
Information). The multidisciplinary guideline development
group (GDG) comprised medical specialists (consultants in der-
matology, paediatric dermatology, rheumatology, virology and
obstetric medicine), a clinical nurse specialist, dermatology trai-
nees, a pharmacist specialist, a patient representative and a
research team providing technical and methodological support
[a full list of GDG members can be found in Appendix K (File
S2; see Supporting Information)].
The recommendations were developed for implementation in
the National Health Service (NHS) in the UK. The guideline rec-
ommendations will normally fall within licensed indications;
exceptionally, and only if clearly supported by evidence, use
outside a licensed indication may be recommended. The guide-
line assumes that prescribers cross-reference a drug’s summary
of product characteristics (SPC) to inform clinical decision mak-
ing for individual patients. Where relevant, this guidance
applies to biosimilars (similar biological medical products),
subject to recommendations given within the BAD position
statement and the European Medicines Agency guidelines.5,6
This guidance does not cover agents licensed outside the UK or
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use of biologic therapies for indications other than psoriasis, or
use when psoriatic arthritis is the main indication.
Summary of recommendations
These evidence- and consensus-based (good practice point,
GPP) recommendations should be considered in the context of
the individual needs of the patient, with cross-reference to the
relevant drug’s SPC and the Implementation Toolkit (File S1:
Tables S1–S5; see Supporting Information). The strength of rec-
ommendation is expressed by the wording and symbols fea-
tured in Table 1. The supporting information for the guideline
details the systematic review of the newly identified evidence
underpinning the updated or new recommendations (File S2;
Appendices A–M see Supporting Information); Appendix D,
‘linking evidence to recommendations’ (LETR), describes the
factors that were taken into consideration for each of these rec-
ommendations, which should be read in conjunction with the
full version of the 2017 guidelines.1 A pathway algorithm based
on the recommendations to guide choice of biologic therapy in
adults with psoriasis is shown in Figure 1.
Using biologic therapy
R1 (↑↑) Initiation and supervision of biologic therapy for peo-
ple with psoriasis should be undertaken by specialist physi-
cians experienced in the diagnosis and treatment of psoriasis.
Routine monitoring may be delegated to other healthcare pro-
fessionals, for example clinical nurse specialists. Manage psori-
atic arthritis and/or multimorbidity in consultation with the
relevant healthcare professionals.
R2 (↑↑) Agree and formalize arrangements for drug adminis-
tration, monitoring and follow-up between health carers and
the person receiving treatment.
R3 (↑↑) Offer people with psoriasis who are starting biologic
therapy the opportunity to participate in long-term safety reg-
istries (the British Association of Dermatologists Biologics and
Immunomodulators Registry, BADBIR, in the UK and Republic
of Ireland; www.badbir.org).
Criteria for biologic therapy
R4 (↑↑) Offer biologic therapy to people with psoriasis
requiring systemic therapy if methotrexate and ciclosporin
have failed, are not tolerated or are contraindicated [see
National Institute for Health and Care Excellence (NICE)
guidelines CG153]7 and the psoriasis has a large impact on
physical, psychological or social functioning [for example,
Dermatology Life Quality Index (DLQI) or Children’s DLQI >
10 or clinically relevant depressive or anxiety symptoms] and
one or more of the following disease severity criteria apply:
• the psoriasis is extensive [defined as body surface area (BSA)
> 10% or Psoriasis Area and Severity Index (PASI) ≥ 10]
• the psoriasis is severe at localized sites and associated with
significant functional impairment and/or high levels of
distress (for example nail disease or involvement of high-
impact and difficult-to-treat sites such as the face, scalp,
palms, soles, flexures and genitals).
R5 (↑) Consider biologic therapy earlier in the treatment path-
way (e.g. if methotrexate has failed, is not tolerated or is con-
traindicated) in people with psoriasis who fulfil the disease
severity criteria and who also have active psoriatic arthritis (see
the NICE musculoskeletal conditions overview)8 or who have
psoriasis that is persistent, i.e. that relapses rapidly (defined as >
50% baseline disease severity within 3 months of completion of
any treatment) off a therapy that cannot be continued in the
long term (e.g. narrowband ultraviolet B and ciclosporin).
Prescribing biologic therapy
R6 (↑↑) Be aware of the benefits of, contraindications to and
adverse effects associated with biologic therapies and reference
the drug-specific SPCs (www.medicines.org.uk/emc).
R7 (↑↑) Provide high-quality, evidence-based information to
people being prescribed biologic therapies. Explain the risks
Table 1 Strength of recommendation ratings
Strength Wording Symbols Definition
Strong recommendation for





↑↑ Benefits of the intervention outweigh the risks; most patients would
choose the intervention while only a small proportion would not;
for clinicians, most of their patients would receive the intervention;
for policymakers, it would be a useful performance indicator
Weak recommendation for
the use of an intervention
‘Consider’ ↑ Risks and benefits of the intervention are finely balanced; many patients
would choose the intervention but many would not; clinicians would
need to consider the pros and cons for the patient in the context of the
evidence; for policymakers, it would be a poor performance indicator
where variability in practice is expected
No recommendation Θ Insufficient evidence to support any recommendation
Strong recommendation against
the use of an intervention
‘Do not offer’ ↓↓ Risks of the intervention outweigh the benefits; most patients would not
choose the intervention while only a small proportion would; for
clinicians, most of their patients would not receive the intervention
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and benefits to people undergoing this treatment (and their
families or carers where appropriate), using absolute risks and
natural frequencies when possible (see File S1: Table S2: Deci-
sion Aid; see Supporting Information). Explain the treatment
regimen and importance of treatment adherence. Allow them
adequate time to consider the information. See also R14.
R8 (↑↑) Support and advice should be offered to people with
psoriasis (and their families or carers where appropriate) by
healthcare professionals who are trained and competent in the
use of biologic therapies.
Reviewing biologic therapy
R9 (↑↑) Assess initial response to biologic therapy in people
with psoriasis at time points appropriate for the drug in ques-
tion, and then on a regular basis during therapy (e.g. every 6
months); see the Summary of licensed indications and posol-
ogy in File S1: Table S1 in the Supporting Information.
R10 (↑↑) Review the response to biologic therapy by taking
into account:
• psoriasis disease severity compared with baseline (e.g. PASI
baseline to endpoint score)9
• the agreed treatment goal
• control of psoriatic arthritis disease activity and/or inflam-
matory bowel disease (in consultation with a rheumatolo-
gist and/or gastroenterologist)
• the impact of psoriasis on the person’s physical, psycho-
logical and social functioning
• the benefits vs. the risks of continued treatment
• the views of the person undergoing treatment (and their
family or carers, where appropriate)
• adherence to the treatment.
R11 (↑↑) Assess whether the minimal response criteria have
been met, as defined by:
• a 50% or greater reduction in baseline disease severity
(e.g. PASI 50 response, or percentage BSA where PASI is
not applicable) and
• clinically relevant improvement in physical, psychological
or social functioning (e.g. ≥ 4-point improvement in DLQI
or resolution of low mood).
R12 (↑) Consider changing to an alternative therapy, includ-
ing another biologic therapy, if any of the following applies:
• the psoriasis does not achieve the minimum response cri-
teria (primary failure – see R11)
• the psoriasis initially responds but subsequently loses this
response (secondary failure)
• the current biologic therapy cannot be tolerated or
becomes contraindicated.
Choice of biologic therapy: general considerations
R13 (↑↑) Before initiating or making changes to biologic ther-
apy, take into account both psoriasis and psoriatic arthritis and
manage treatment in consultation with a rheumatologist or
paediatric rheumatologist. Be aware that the presence of and
phenotype of psoriatic arthritis (e.g. peripheral vs. axial dis-
ease) may influence access to, choice of and dose of biologic
therapy. Actively screen for psoriatic arthritis (in people with-
out this diagnosis), using a validated tool, e.g. Psoriasis Epi-
demiology Screening Tool (PEST), and be aware that the PEST
may not detect axial arthritis/inflammatory back pain.
R14 (↑↑) Tailor the choice of agent to the needs of the per-
son. Take into account the following factors (see File S1:
Table S2: Decision Aid in the Supporting Information):
Psoriasis factors:
• the goal of therapy [for example, Physician’s Global
Assessment of clear or nearly clear]
• disease phenotype and pattern of activity
• disease severity and impact
• the presence of psoriatic arthritis (in consultation with an
adult or paediatric rheumatologist)
• the outcomes of previous treatments for psoriasis.
Other individual factors:
• person’s age
• past or current comorbid conditions (e.g. inflammatory
bowel disease, heart failure)
• conception plans
• body weight
• the person’s views and any stated preference on adminis-
tration route or frequency
• likelihood of adherence to treatment.
Drug costs:
• including administration costs, dosage, price per dose and
commercial arrangements.
Choice of biologic therapy in adults
R15 (↑↑) Offer any of the currently licensed biologic therapies
as first-line therapy (and with reference to R18 and R19) to
adults with psoriasis who fulfil the criteria for biologic therapy
(see R4 and R5), using the Decision Aid (see File S1: Table S2 in
the Supporting Information) to inform treatment choice.
R16 (↑↑) Offer any of the currently licensed biologic therapies
(and with reference to R18 and R19) when psoriasis has not
responded to a first biologic therapy. Use the Decision Aid
(see File S1: Table S2 in the Supporting Information) and take
into account all factors detailed in R14 to select the most
appropriate agent.
R17 (↑↑) Offer a TNF antagonist (and with reference to R18
and R19) or an IL-17 antagonist* as a first-line therapy to
adults with psoriasis and who also have psoriatic arthritis,
using the Decision Aid (see File S1: Table S2 in the Supporting
Information) to inform treatment choice.10–13 *Please note
that brodalumab is not licensed for psoriatic arthritis.
R18 (↑) Consider etanercept for use in people where a TNF
antagonist is indicated and other available biological agents have
failed or cannot be used, or where a short half-life is important.
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Figure 1 Pathway algorithm to guide choice of biologic therapy in adults with psoriasis. This guidance applies to biosimilars, subject to
recommendations given within the British Association of Dermatologists position statement and European Medicines Agency guidelines.6
aTake into account both psoriasis and psoriatic arthritis before initiating or making changes to biologic therapy, and manage treatment in
consultation with a rheumatologist; be aware that the presence of and phenotype of psoriatic arthritis (for example, peripheral vs. axial disease)
may influence access to, choice of and dose of biologic therapy. bTake into account psoriasis factors (the goal of therapy, e.g. Physician’s Global
Assessment clear or nearly clear, disease phenotype and pattern of activity, disease severity and impact, presence of psoriatic arthritis, outcomes of
previous treatment for psoriasis); other individual factors (age, past or current comorbid conditions, conception plans, body weight, the person’s
views and any stated preference on administration route or frequency, adherence); and drug costs (including administration costs, dosage, price
per dose and commercial arrangements). cConsider changing to an alternative biologic therapy if any of the following applies: the psoriasis does
not achieve the minimum response criteria (primary failure: see R11) or the psoriasis initially responds but subsequently loses this response
(secondary failure). dConsider escalating the dose of/reducing the interval for biologic therapy in adults (R20) when an inadequate primary
response may be due to insufficient drug exposure (e.g. in people who are obese and/or whose psoriasis relapses during the treatment cycle and/
or if the drug level is known to be subtherapeutic). Take into account that dose escalation/interval reduction may be associated with an increased
risk of infection, and, depending on the drug, it may be off-licence and not funded. Currently, a dose-escalation/interval-reduction strategy is not
applicable to brodalumab, guselkumab, risankizumab or secukinumab. IL, interleukin; TNF, tumour necrosis factor
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R19 (↑↑) Reserve infliximab for use in people with very sev-
ere disease, or where other available biological agents have
failed or cannot be used, or where weight-based dosing is a
priority.
When to consider dose escalation/interval reduction
R20 (↑) Consider escalating the dose of or reducing the inter-
val for biologic therapy in adults (see Table 2) and when an
inadequate primary response might be due to insufficient
drug exposure (e.g. in people who are obese and/or whose
psoriasis relapses during the treatment cycle and/or if the
drug level is known to be subtherapeutic). Take into account
that this may be associated with an increased risk of infec-
tion/adverse events and, depending on the drug, off-licence
(see Table 2) and may not be approved by NICE and there-
fore not funded.
What to do when a second or subsequent biologic
therapy fails in adults
R21 (↑↑) When a person’s psoriasis responds inadequately to
a second or subsequent biological agent, review treatment
goals, seek advice from a dermatologist with expertise in bio-
logic therapy and consider any of the following strategies:
• reiterate advice about modifiable factors contributing to
poor response such as obesity and poor adherence (inten-
tional or nonintentional)
• consider whether drug exposure is adequate (see R20)
• optimize adjunctive therapy (e.g. switch from oral to sub-
cutaneous methotrexate)
• switch to an alternative biological agent
• alternative or supplementary nonbiologic therapy
approaches (e.g. inpatient topical therapy, phototherapy or
systemic therapies).
Choice of biologic therapy in children and young people
R22 (↑↑) Offer adalimumab (age ≥ 4 years), etanercept (≥ 6
years) or ustekinumab (≥ 12 years) to children and young people
who fulfil the criteria for biologic therapy (see also R4 and R5).
R23 (↑↑) When a child’s or young person’s psoriasis responds
inadequately to a first or subsequent biological agent seek
advice from a dermatologist with expertise in biologic therapy
in this age group and consider any of the following strate-
gies:
• reiterate advice about modifiable factors contributing to
poor response (e.g. obesity and poor adherence)
• optimize adjunctive therapy (e.g. switch from oral to sub-
cutaneous methotrexate)
• switch to an alternative biological agent
• alternative or supplementary nonbiologic therapy approaches
(e.g. inpatient topical therapy or systemic therapies).
Transitioning to or between biologic therapies
R24 (↑↑) When choosing the transitioning strategy from one
drug therapy to another and whether a therapy washout (or
no washout) should be used, take into consideration:
• the pharmacology of the drugs that are being stopped and
started (see File S1: Table S1: Summary of licensed indica-
tions and posology, in the Supporting Information)
• the person’s clinical circumstances (see R14)
• the person’s views on the risks and benefits of transition-
ing option(s).
R25 (↑) When transitioning from standard systemic therapy
to biologic therapy consider these:
• in stable disease, aim to allow 1 month to elapse between
the last dose of any current standard systemic immunosup-
pressant psoriasis therapy (except methotrexate) and the
planned date of biologic initiation
• start a biologic therapy with no drug washout period in
people taking methotrexate, or in people on other thera-
pies where this would lead to unstable disease
• when standard, systemic immunosuppressant therapy can-
not be stopped (e.g. in people for whom a disease flare
would be severe or hazardous), rationalize use of therapy
and stop as soon as possible (e.g. when a minimum
response has been achieved).
R26 (↑) When transitioning to a new biologic therapy (from
a previous biologic therapy) consider using a 1-month wash-
out period, or the length of the treatment cycle (whichever is
longer), between the last dose of the current biologic therapy
and the planned date of biologic initiation.
Table 2 Dose-escalation/interval-reduction strategy
Biological agent Suggested dose-escalation/interval-reduction strategy
Adalimumab 40 mg every other week Adalimumab 40 mg weekly
Certolizumab pegol 200 mg every 2 weeks Certolizumab pegol 400 mg every 2 weeks
Etanercept 50 mg once weekly Etanercept 50 mg twice weekly
Infliximab 5 mg kg1 every 8 weeks aInfliximab 5 mg kg1 every 6 weeks
Ixekizumab 80 mg every 4 weeks aIxekizumab 80 mg every 2 weeks
Tildrakizumab 100 mg every 12 weeks Tildrakizumab 200 mg every 12 weeks (high disease burden or ≥ 90 kg)
Ustekinumab 45 mg every 12 weeks (≤ 100 kg) aUstekinumab 90 mg every 8 or 12 weeks (≤ 100 kg)
Ustekinumab 90 mg every 12 weeks (> 100 kg) aUstekinumab 90 mg every 8 weeks (> 100 kg)
aOff-license use.
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Conception and pregnancy
R27 (↑↑) Advise women of childbearing potential, who are
starting biologic therapy for psoriasis, to use effective contra-
ception and to discuss conception plans with the consultant
supervising their care (see R29). There are no known interac-
tions between biologic therapies and contraceptive methods
(see drug-specific SPCs).
R28 (↑↑) For women planning conception or who are
pregnant, provide information about what is known about the
effects of biologic therapy (see drug-specific SPCs), including
these:
• the importance of controlling severe or unstable psoriasis
to maintain maternal health
• most of the available evidence relates to TNF antagonists in
women with rheumatological or inflammatory bowel disease
• most pregnancies reported in women exposed to TNF
antagonists at conception and/or during pregnancy have
successful outcomes, with no increase in stillbirths, congen-
ital malformations, preterm births or neonatal infections
• exposure to TNF antagonists during pregnancy may
increase the risk of maternal infection
• maternal IgG, and therefore biological drugs currently
licensed for psoriasis (with the exception of certolizumab
pegol), is actively transferred to the developing fetus dur-
ing the second and third trimesters and the impact of this
on neonatal development and risk of infection has not
been adequately studied
• certolizumab pegol transfer across the placenta is low or
negligible
• in general, live vaccines must be avoided for the first 6
months of life in infants born to mothers taking biologic
therapy beyond 16 weeks’ gestation (see drug-specific SPCs)
• relevant patient information resources.14
R29 (↑↑) Discuss the risks and benefits of using biologic ther-
apy in women who are planning conception or who are preg-
nant. Offer advice on a case-by-case basis by taking into
account the woman’s views and:
• the available evidence (see R28)
• her current disease status
• the course of psoriasis disease and the fetal outcome dur-
ing any prior pregnancies
• the risk of severe or unstable psoriasis without biologic
therapy
• her physical, psychological and social functioning without
biologic therapy
• the options for alternative treatment strategies in the event
of disease flare.
R30 (↑) If the decision to use biologic therapy when planning
conception or during pregnancy has been made:
• consider using certolizumab pegol as a first-line choice
when starting biologic therapy in women planning con-
ception
• consider stopping biologic therapy in the second/third tri-
mester to minimize fetal exposure and limit the potential
risk to the neonate, taking into account individual biolog-
ics’ pharmacokinetics and transfer across the placenta (File
S1: Table S1: Summary of licensed indications and posol-
ogy; see Supporting Information)
• consider using ciclosporin or certolizumab pegol as first-
line options when it is necessary to start a systemic ther-
apy during the second or third trimester.
R31 (GPP) Consider continuing or restarting biologic
therapy in women wishing to breastfeed. Explain the benefits of
breastfeeding and that the small amounts of biologic therapy pre-
sent in breast milk are unlikely to be absorbed systemically by the
infant.
R32 (↑↑) Ensure consultation and information sharing across
specialities, including with an obstetrician who has expertise
in caring for pregnant women with medical problems. Collect
pregnancy outcome data for safety registries, for example
BADBIR in the UK and Republic of Ireland.
R33 (↑↑) Be aware that limited evidence reports that use of
TNF antagonist therapy by men around the time of conception
resulted in successful outcomes in most pregnancies, with no
increased risk of congenital malformations, preterm births or
small for gestational age infants.
Biologic therapy and cancer risk
R34 (↑↑) Assess people with psoriasis prior to, and during
treatment with, biologic therapy with respect to:
• their past or current history of cancer (see R36 and R37)
and/or
• any future risk of cancer.
R35 (↑↑) Provide information to people with psoriasis about
the importance of participating in national cancer screening
programmes.
R36 (↑↑) Exercise caution and discuss with the relevant cancer
specialist when prescribing biologics in people with psoriasis and:
• a history of cancer, particularly if this has been diagnosed
and treated less than 5 years previously and/or
• where the baseline risk of skin cancer is increased.
R37 (↑↑) Discuss the risks and benefits of continuing vs. stop-
ping biologic therapy in patients who develop or have completed
recent treatment for cancer. Offer advice on a case-by-case basis
by taking into account the advice from the treating oncologist,
multidisciplinary team discussion and patient choice considering:
• the risk of severe or unstable psoriasis if the biologic ther-
apy were stopped
• the physical, psychological and social functioning if the
biologic therapy were stopped
• the options for alternative treatment strategies
• the impact of cancer progression/recurrence.
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Biologic therapy and infections
R38 (↑↑) Assess people with psoriasis prior to, and during
treatment with, biologic therapy with respect to:
• risk factors for infection (e.g. comorbidities, cotherapy,
lifestyle and travel)
• known infections (past or current)
• signs or symptoms suggestive of infection.
Biologic therapy and chronic viral infections – hepatitis
B, hepatitis C and HIV
R39 (↑↑) Test for hepatitis B (surface antigen and core antibody),
hepatitis C (IgG) and HIV (HIV-1 and HIV-2 antibodies and HIV-
1 antigen) infection in people starting biologic therapy.
R40 (↑) Consider ongoing screening (e.g. annually) for hep-
atitis B, hepatitis C and HIV, particularly in people who are at
increased risk of infection (File S1: Table S5: Groups at
increased risk of tuberculosis, hepatitis B, hepatitis C and HIV;
see Supporting Information).15
R41 (↑↑) Retest for viral hepatitis in any person who develops
unexplained transaminitis (raised alanine aminotransferase
and/or aspartate aminotransferase); retest for HIV infection in
any person who has symptoms or other conditions that might
represent HIV seroconversion/infection.
R42 (↑↑) Consult a hepatitis specialist when treating all people
with biologic therapy who have hepatitis B or C infection,
whether newly diagnosed or previously known.
R43 (↑↑) Provide treatment options to people with psoriasis
who are HIV seropositive on a case-by-case basis; be aware
that severe psoriasis can occur in people with uncontrolled
HIV infection. Involve relevant specialists and ensure HIV viral
load is suppressed on antiretroviral therapy before considering
biologic therapy.
R44 (GPP) Test for varicella zoster (VZ) virus antibody in peo-
ple with a negative or uncertain history for chickenpox before
starting biologic therapy. Consider varicella vaccination before
initiating biologic therapy in those who are not varicella immune
and seek expert advice. Be aware of the indications for postexpo-
sure prophylaxis in VZ-susceptible individuals taking biologics,
with VZ immunoglobulin or oral aciclovir/valaciclovir.16
Use of biologic therapy and tuberculosis
R45 (↑) Consider screening for latent tuberculosis
(TB) with an interferon-gamma release assay (IGRA) alone, or
with an IGRA and concurrent Mantoux test; be aware of the
individual’s risk factors for TB when interpreting results.17
R46 (↑↑) Apply local policy on the use of a plain chest radio-
graph for screening for TB to rule out abnormalities at base-
line including granulomas indicative of prior infection and
other confounding lung diseases. If positive, assess for active
TB and/or management of latent TB in consultation with a TB
specialist (see NICE tuberculosis guideline).17
R47 (GPP) In people who require treatment for latent TB [3
months of isoniazid (with pyridoxine) and rifampicin, or 6
months of isoniazid (with pyridoxine)], aim to complete 2
months of treatment before commencing biologic therapy.
R48 (GPP) Any symptoms or signs suggestive of TB, new
exposure to TB or prolonged residence in a high-incidence set-
ting should prompt further clinical assessment and investiga-
tion, including a repeat IGRA. Be aware that active TB on TNF
antagonist therapy is often disseminated and extrapulmonary;
symptoms may include unexplained weight loss, night sweats,
nonresolving cough, haemoptysis and lymphadenopathy.
R49 (GPP) Inform people that they should seek medical advice
if symptoms of TB develop during or after treatment with a bio-
logic therapy and issue a patient alert card in line with Medici-
nes and Healthcare products Regulatory Agency guidance.18
Biologics and vaccination
R50 (↓↓) Do not give live vaccines to people on biologic ther-
apy or to infants (up to 6 months of age) whose mothers
have received biologic therapy beyond 16 weeks’ gestation.
Please check individual drug SPC.
R51 (↑↑) Stop biologic therapy for 6–12 months before giv-
ing live vaccines, e.g. the varicella and shingles (herpes zoster)
vaccine. Be aware that the UK Green Book (Immunisation Against
Infectious Disease)19 has recently advised increasing the interval
from 6 to 12 months; expert opinion suggests the interval
required will vary depending on the pharmacokinetic/pharma-
codynamic profile of each drug and should be determined on
a case-by-case basis, taking into account the SPC drug specifi-
cations and expert advice. Biologic therapy can be started 4
weeks after administration of a live vaccine.
R52 (↑↑) Provide people on biologic therapy with informa-
tion on safe use of vaccinations including which vaccination
should be used and which to avoid (see BAD Patient Informa-
tion Leaflet on immunization, www.bad.org.uk/leaflets, and
the Green Book,19 with reference to the clinical risk category
‘immunosuppression’).
R53 (↑↑) Where possible, complete all required vaccinations
prior to initiation of biologic therapy and review vaccination
requirements during therapy with reference to the Green
Book19 and the clinical risk category ‘immunosuppression’.
Important contraindications to biologic therapies
R54 (GPP) Do not use TNF antagonists in people with demyeli-
nating diseases and consider alternative interventions in people
who have a first-degree relative with demyelinating disease.
R55 (GPP) Stop treatment and seek specialist advice if neuro-
logical symptoms suggestive of demyelinating disease develop
© 2020 The Authors. British Journal of Dermatology
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during TNF antagonist therapy. Symptoms include loss or
reduction of vision in one eye with painful eye movements;
double vision; ascending sensory disturbance and/or weak-
ness; problems with balance, unsteadiness or clumsiness;
altered sensation travelling down the back and sometimes into
the limbs when bending the neck forwards (Lhermitte symp-
tom); please see NICE guidelines CG186.20
R56 (GPP) Avoid TNF antagonist therapy in people with sev-
ere cardiac failure [New York Heart Association (NYHA) class
III and IV].
R57 (GPP) Assess people with well-compensated (NYHA class I
and II) cardiac failure (see the NICE pathway)21 and consult with
a cardiology specialist before using TNF antagonist therapy.
R58 (GPP) Stop TNF antagonist therapy in the event of new or
worsening pre-existing heart failure and seek specialist advice.
R59 (GPP) Exercise caution and consult a gastroenterology
specialist before using brodalumab, ixekizumab or secuk-
inumab in people with inflammatory bowel disease.
R60 (GPP) In people undergoing elective surgery, balance the
risk of postoperative infection against the risk of developing
severe or unstable disease by stopping biologic therapy. Advise
stopping biologic therapy 3–5 times the half-life of the drug
in question (File S1: Table S1: Summary of licensed indica-
tions and posology; see Supporting Information) or the length
of the treatment cycle (whichever is longer) between the last
dose of therapy and the planned surgery. Inform the surgical
team that the patient may be at a higher risk of infection post-
operatively. Restart biologic therapy postoperatively if there is
no evidence of infection and wound healing is satisfactory.
Implementation toolkit
To support implementation of the recommendations, a number
of documents have been developed (see File S1: Implementa-
tion Toolkit, including the Decision Aid, in the Supporting
Information). These comprise a summary of licensed indica-
tions and posology for biologic therapy (Table S1); a Decision
Aid, informed by the evidence reviews, to help patients and
clinicians choose the appropriate biologic therapy (Table S2);
absolute effects of biological drugs at licensed doses relative to
placebo (Table S3); a suggested schedule for screening and
monitoring (Table S4) and a list of groups at increased risk of
tuberculosis, hepatitis B, hepatitis C and HIV (Table S5).
Audit standards, data items and data-
collection methodology
Dermatology teams involved in prescribing biological inter-
ventions should use audit as a tool to monitor their service
against national guidelines of care. The aim should be to
ensure that the service is high in quality, safe and cost-effec-
tive. For further details see File S3: Audit standards in the Sup-
porting Information.
Stakeholder involvement and peer review
The guideline and supplementary information was made avail-
able to the BAD membership, British Society for Paediatric Der-
matology, British Dermatological Nursing Group, Primary Care
Dermatological Society, British Society for Paediatric and Ado-
lescent Rheumatology, British Society of Rheumatology, Royal
College of Obstetrics and Gynaecology, Psoriasis and Psoriatic
Arthritis Alliance, Psoriasis Association and relevant pharmaceu-
tical companies (see File S2: Appendix M in the Supporting
Information for the full list of stakeholders), comments from
whom were actively considered by the GDG. The finalized ver-
sion was peer reviewed by the Clinical Standards Unit of the
BAD, made up of the Therapy & Guidelines subcommittee, prior
to submission for publication.
Limitations of the guideline
This document has been prepared on behalf of the BAD and is
based on the best data available when the document was pre-
pared. It is recognized that under certain conditions it may be
necessary to deviate from the guidelines and that the results of
future studies may require some of the recommendations
herein to be changed. Failure to adhere to these guidelines
should not necessarily be considered negligent, nor should
adherence to these recommendations constitute a defence
against a claim of negligence. Limiting the review to English-
language references was a pragmatic decision, but the authors
recognize that this might exclude some important information
published in other languages.
Plans for guideline revision
This 2020 guideline updates the previous version.1 An annual
literature review is planned for this fast-moving subject and the
recommendations updated where necessary, in line with the
BAD’s recommended guideline development methodology.2
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